Suchergebnisse - "Tsuboi, Masahiro"

PubPharm (43)

1

Summary of Research : Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

enthalten in: Targeted oncology | 2024

von Tsuboi, M. | Herbst, R. | John, T. | +18

2

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC : translational research of phase III IMPACT study

enthalten in: Molecular oncology | 2024

von Ikeda, S. | Tsuboi, M. | Sakai, K. | +29

3

Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Kitagawa, S. | Zenke, Y. | Taki, T. | +14

4

EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system

enthalten in: International journal of clinical oncology | 2024

von Nomura, K. | Aokage, K. | Kaminuma, Y. | +10

5

Osimertinib in Resected EGFR-Mutated NSCLC. Reply

enthalten in: The New England journal of medicine | 2023

von Tsuboi, M. | Herbst, R. | Wu, Y.

CommentOn: N Engl J Med. 2023 Jul 13;389(2):137-147. - PMID 37272535

6

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC : Updated Analysis From the Phase 3 ADAURA Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von John, T. | Grohé, C. | Goldman, J. | +17

7

Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations : A Review

enthalten in: JAMA oncology | 2023

von Passaro, A. | Mok, T. | Attili, I. | +4

8

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

enthalten in: The New England journal of medicine | 2023

von Tsuboi, M. | Herbst, R. | John, T. | +118

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):504. - PMID 37311902

9

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer : Updated Results From the Phase III Randomized ADAURA Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Herbst, R. | Wu, Y. | John, T. | +22

ErratumIn: J Clin Oncol. 2023 Aug 1;41(22):3877. - PMID 37104731

10

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases : Current Evidence and Future Perspectives on Therapeutic Strategies

enthalten in: Targeted oncology | 2023

von Popat, S. | Ahn, M. | Ekman, S. | +7

ErratumIn: Target Oncol. 2023 Feb 8;:. - PMID 36752975

1
2
3
4
5
Nächster »
[5]